Home » Topics » BioWorld Science

BioWorld Science
RSS

Verona initiates phase IIb study of nebulized ensifentrine in moderate to severe COPD

May 7, 2019

Onxeo treats first patient in phase Ib study of AsiDNA for solid tumors

May 7, 2019

Sunshine Lake Pharma divulges compounds for HBV infections

May 7, 2019

European Commission approves Palynziq to treat PKU

May 7, 2019

Skyhawk and Takeda collaborate to develop small-molecule treatments for neurodegenerative diseases

May 7, 2019

Shanghai Longwood Biopharmaceuticals identifies PD-1/PD-L1 inhibitors

May 7, 2019

Esteve Pharmaceuticals presents new analgesics

May 7, 2019

Gilead Sciences divulges new HIV protease inhibitors

May 7, 2019

FDA approves Vyndaqel and Vyndamax for the treatment of cardiomyopathy caused by ATTR-CM

May 7, 2019

Adaptimmune announces clinical progress with ADP-A2M4 in synovial sarcoma and other solid tumors

May 7, 2019

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
AA meeting of minds as PTC, Novartis push votoplam in HD
BioWorld
What PTC Therapeutics Inc.’s latest data with votoplam might mean in the Huntington’s disease (HD) landscape became grist for Wall Street after the firm unveiled...
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...